Perthera, LCA Collaborate
Perthera, LCA Collaborate
Complete the form below and we will email you a PDF version of "Perthera, LCA Collaborate"
Perthera Inc has announced a partnership with Lung Cancer Alliance (LCA) to offer precision medicine services at no-cost for patients who have been diagnosed with lung cancer. The service includes comprehensive molecular analysis of a patient’s tumor leveraging the expertise of various medical specialists including oncologists, medical researchers and computational biologists who work as partners on the patient’s cancer care team.
Lung cancer is the leading cancer killer in both men and women in the U.S., with almost 160,000 Americans expected to die from it in 2016, accounting for approximately 27 percent of all cancer deaths. Andrew Mignatti, CEO and president of Perthera, said that precision medicine has often been wrongly defined as the equivalent of genomic medicine. “Understanding the patient’s genomic makeup is a very significant part of the precision medicine analysis, but it is hardly enough,” he said.
“In addition to genomic analysis, for example, patients who use our program will have proteomic testing so that protein-level and protein activation level changes, which are often more relevant to treatment response, can be identified. In addition to quantitative analysis by tissue testing and computer analysis, Perthera provides medical expertise by its own team, and also provides dedicated service in response to the patient’s needs and requests.
Emanuel Petricoin, PhD, Chief Scientific Officer and co-founder of Perthera said the company’s unique multi-omic-based precision medicine service provides the broadest molecular analysis that a patient can get using commercial testing platforms. He said that “the benefit to the patient and their treating physicians is that the more actionable information they obtain, the more chances of identifying a successful treatment option for each patient.”
“We are excited about the potential of this effort to increase access to this type of testing,” said Jennifer C. King, PhD, Director of Science and Research, Lung Cancer Alliance. “Now, more than ever, having detailed knowledge about the characteristics of a tumor is a critical component to determining a patient’s most effective treatment options and this program makes that a reality no matter where that patient may be.”
Source: Story from Perthera Inc. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.